Table 1.

Patient Demographics and Clinical Characteristics (N = 44)

Characteristic	Value
Age, median (range), yr	62.5 (35.0–74.0)
Sex, n (%)
Female	15 (34.9)
Male	28 (65.1)
Unknown	1
Race, n (%)
White	43 (97.7)
Black/African American	1 (2.3)
Marital status, n (%)
Single	2 (4.7)
Married/partner	37 (86.0)
Separated	1 (2.3)
Divorced	1 (2.3)
Widowed	2 (4.7)
Unknown	1
Currently employed, n (%)
No	29 (72.5)
Yes	11 (27.5)
Unknown	4
Type of myelofibrosis at registration, n (%)
PMF	25 (58.1)
Post ET-MF	9 (20.9)
Post PV-MF	9 (20.9)
Unknown	1
Years since MF diagnosis, median (range)	2.0 (0.0–21.0)
Presence of JAK2V617F mutation, n (%)
Yes	31 (72.1)
No	12 (27.9)
Unknown	1
History of hemorrhage, n (%)
Yes	3 (7.0)
No	40 (93.0)
Unknown	1
History of thrombosis, n (%)
Yes	9 (21.4)
No	33 (78.6)
Unknown	2
DIPSS total score (0–6): pretransplant, n (%)
0 (low risk)	2 (4.5)
2 (intermediate 1)	6 (13.6)
3 (intermediate 2)	10 (22.7)
4 (intermediate 2)	10 (22.7)
5 (high)	15 (34.1)
6 (high)	1 (2.3)
RBC transfusion in prior month, n (%)
Yes	19 (44.2)
No	24 (55.8)
Unknown	1
Platelet transfusion in prior month, n (%)
Yes	4 (9.8)
No	37 (90.2)
Unknown	3
Current spleen size by exam, median (range), cm	10.0 (0.0–27.0)
Type of allogeneic stem cell transplant, n (%)
HLA-identical related	11 (26.8)
HLA-mismatched related	1 (2.4)
HLA-identical unrelated	24 (58.5)
HLA-mismatched unrelated	5 (12.2)
Unknown	3
Conditioning regimen, n (%)
RIC Bu/Flu	16 (40.0)
RIC Flu/thiotepa/busulfan	2 (5.0)
FLASMA-Bu	8 (20.0)
RIC treosulfan/Flu	3 (7.5)
MAC Bu/Flu	4 (10.0)
RIC FBM	7 (17.5)
Unknown	4
Conditioning level, n (%)
High dose	6 (15.8)
Reduced/low intensity	32 (84.2)
Missing	6
GVHD prophylaxis, n (%)
CNI/MMF	28 (70.0)
CNI/MTX	12 (30.0)
Missing	4
ATG, n (%)
Yes	32 (80.0)
No	8 (20.0)
Unknown	4
HSCT donor/patient ABO compatible, n (%)
Yes	18 (40.0)
No	26 (59.1)
CMV positive, n (%)
Yes	16 (36.4)
No	28 (63.6)

PMF indicates primary myelofibrosis; ET-MF, essential thrombocytosis myelofibrosis; PV-MF, polycythemia vera myelofibrosis; DIPSS, Dynamic International Prognostic Scoring System; RIC, reduced-intensity conditioning; Bu, Busulfan; Flu, Fludarabine; FLASMA, fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide; MAC, myeloablative conditioning; FBM, Fludarabine, carmustine, melphalan; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; MTX, methotrexate; ATG, anti-thymocyte globulin; HSCT, hematopoietic stem cell transplantation; CMV, cytomegalovirus.